Clinical response defined by reduction of CDAI score by ≥ 100 at week 6 · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in clinical response defined by reduction of CDAI score by ≥ 100 at… compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review
Clinical remission defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks · Patients with active Crohn's disease
It is very uncertain whether infliximab 5–10 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with placebo (very low certainty).
1 finding from 1 review
Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease
It is very uncertain whether infliximab 5–10 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with placebo (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Infliximab 5 mg/kg and purine analogues probably leads to higher clinical remission as defined by the studies at weeks 24–26 compared with purine analogues alone (moderate certainty).
1 finding from 1 review
Clinical response as defined by the studies at week 26 · Patients with active Crohn's disease
Infliximab 5 mg/kg and purine analogues probably leads to higher clinical response as defined by the studies at week 26 compared with purine analogues alone (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg and purine analogues showed no clear difference in withdrawals due to adverse events at week 26 compared with purine analogues alone (low certainty).
1 finding from 1 review
Failure to maintain clinical remission at end of study · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol probably leads to lower failure to maintain clinical remission at week 26(1 RCT, 428… compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.73 [0.63, 0.85]
Studies not reported
Moderate
Failure to maintain clinical response · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol probably leads to lower failure to maintain clinical response at week 26(1 RCT, 428… compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.58 [0.48, 0.71]
Studies not reported
Moderate
Any severe adverse event during maintenance treatment · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).
1 finding from 1 review
RR 0.84 [0.4, 1.78]
Studies not reported
Low
Infectious complications · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes overall infectious complications within 30 days of surgery compared with control (very low certainty).
3 findings from 1 review
OR 1.4 [1.23, 1.6]
41 studies · 41 participants
Very low
OR 1.7 [1.38, 2.09]
17 studies · 17 participants
Low
OR 1.22 [1.03, 1.45]
24 studies · 24 participants
Very low
Incisional infections and wound dehiscence within 30 days of surgery · people with inflammatory bowel disease
Risk of postoperative infectious complications: 5‐ASA led to lower incisional infections and wound dehiscence within 30 days of surgery compared with control; GRADE not reported.
1 finding from 1 review
OR 0.53 [0.3, 0.95]
1 study · 1 participants
GRADE not reported
Intra‐abdominal infectious complications within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: 5‐ASA changes intra‐abdominal infectious complications within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Extra‐abdominal infections within 30 days of surgery · people with inflammatory bowel disease
1 finding from 1 review
Infectious complications · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: immunomodulators changes overall infectious complications within 30 days of surgery compared with control (very low certainty).
3 findings from 1 review
OR 1.11 [0.97, 1.26]
31 studies · 31 participants
Very low
OR 1.29 [0.95, 1.76]
9 studies · 9 participants
Low
OR 1.07 [0.93, 1.24]
22 studies · 22 participants
Very low
Incisional infections and wound dehiscence within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: immunomodulators changes incisional infections and wound dehiscence within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Intra‐abdominal infectious complications within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: immunomodulators changes intra‐abdominal infectious complications within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Extra‐abdominal infections within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: immunomodulators changes extra‐abdominal infections within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Infectious complications · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: anti‐TNF agents changes overall infectious complications within 30 days of surgery compared with control (very low certainty).
3 findings from 1 review
OR 1.27 [1.09, 1.47]
54 studies · 54 participants
Very low
OR 1.6 [1.2, 2.13]
17 studies · 17 participants
Very low
OR 1.14 [0.96, 1.36]
37 studies · 37 participants
Very low